Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29439746 | 1.00 | LMNA (0.45) | LMNAALDH1A1CYP1A2CYP2C9PLA2G1B | |
| SCHEMBL24894558 | 0.89 | LMNA (0.40) | LMNAALDH1A1CYP1A2CYP2C9PLA2G1B | |
| SCHEMBL23969660 | 0.86 | ALDH1A1 (0.43) | LMNAALDH1A1CYP1A2CYP2C9PLA2G1B | |
| SCHEMBL23534358 | 0.84 | ALDH1A1 (0.44) | LMNAALDH1A1CYP1A2CYP2C9PLA2G1B | |
| SCHEMBL27695116 | 0.83 | ALDH1A1 (0.45) | LMNAALDH1A1CYP1A2CYP2C9MAPT | |
| SCHEMBL23969551 | 0.83 | LMNA (0.44) | LMNAALDH1A1CYP1A2CYP2C9PLA2G1B | |
| SCHEMBL30731578 | 0.83 | LMNA (0.44) | LMNAALDH1A1CYP1A2CYP2C9PLA2G1B | |
| SCHEMBL13706557 | 0.83 | ALDH1A1 (0.44) | LMNAALDH1A1CYP1A2CYP2C9PLA2G1B | |
| SCHEMBL2177419 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2C9MAPTGAA | |
| SCHEMBL31463754 | 0.82 | LMNA (0.40) | LMNAALDH1A1CYP1A2CYP2C9PLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2026-05-05 | — | — | US | disclosed |
| EP-4665454-A1 | IMIDAZOTRIAZINE IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| EP-4467199-A2 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2024-11-27 | — | — | EP | disclosed |
| EP-3976597-B1 | SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2024-08-28 | — | — | EP | disclosed |
| WO-2024173173-A1 | IMIDAZOTRIAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| US-20240199605-A1 | SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-20 | — | — | US | disclosed |
| US-20230399515-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | Rakuten Medical, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399515-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | Rakuten Medical, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-28 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-11254673-B2 | Small molecule inhibitors of NF-κB inducing kinase | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-22 | — | — | US | disclosed |
| US-20220010140-A1 | PHTHALOCYANINE DYE COMPOUNDS, CONJUGATES AND METHODS OF USE THEREOF | Rakuten Medical, Inc. | 2022-01-13 | — | — | US | disclosed |
| US-20210300918-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| WO-2020239999-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2020-12-03 | — | — | WO | disclosed |
| US-10710962-B2 | Zwitterionic reagents | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-7741514-B2 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20060281629-A1 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | ISHII YASUTAKA | 2006-12-14 | — | — | US | disclosed |
| US-7115541-B2 | Catalyst comprising n-substituted cyclic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1338336-A1 | CATALYSTS COMPRISING N-SUBSTITUTED CYCLIC IMIDES AND PROCESSES FOR PREPARING ORGANIC COMPOUNDS WITH THE CATALYSTS | Daicel Chemical Industries, Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
| US-20030013603-A1 | Catalyst comprising n-substituted cylic imides and processes for preparing organic compounds with the catalyst | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2003-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300918-A1 | SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, NFRKB | LMNA 2532/4885ALDH1A1 4109/4885CYP1A2 3969/4885 |
| US-11827634-B2 | Small molecule inhibitors of NF-kB inducing kinase | NFKBIA, IKBKB, NFRKB | LMNA 2532/4885ALDH1A1 4109/4885CYP1A2 3969/4885 |
| US-11254673-B2 | Small molecule inhibitors of NF-κB inducing kinase | NFKBIA, IKBKB, CHUK | LMNA 2984/4885ALDH1A1 3934/4885CYP1A2 4056/4885 |
| US-12617789-B2 | Small molecular inhibitors of NF-κb inducing kinase | IRAK3, IKBKB, IKBKG | LMNA 3314/4885ALDH1A1 3824/4885CYP1A2 4708/4885 |
| US-20240199605-A1 | SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE | NFKBIA, IKBKB, IKBKE | LMNA 2913/4885ALDH1A1 4012/4885CYP1A2 4205/4885 |
| US-20060281629-A1 | Catalyst comprising N-substituted cyclic imide compound and process for producing organic compound using the catalyst | NOS2, NOS1, NOS3 | LMNA 4170/4885ALDH1A1 1638/4885CYP1A2 529/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | LMNA 2413/4885ALDH1A1 4368/4885CYP1A2 4880/4885 |
| US-10710962-B2 | Zwitterionic reagents | BTD, HLCS, WIZ | LMNA 699/4885ALDH1A1 4381/4885CYP1A2 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.